LifeMD rises on Q4 2025 beats, 2026 revenue guidance midpoint above consensus
Source: SeekingAlpha
2026-03-09 17:30:19 ET
More on LifeMD
- LifeMD: Still My Favorite Bargain On The Market
- LifeMD: Pure Telehealth Play With In-House Pharmacy Integration
- LifeMD GAAP EPS of -$0.04 beats by $0.02, revenue of $46.9M beats by $1.29M
- GoodRx, LifeMD gain on offerings for Novo’s Wegovy pill
- Seeking Alpha’s Quant Rating on LifeMD
Read the full article on Seeking Alpha
For further details see:
LifeMD rises on Q4 2025 beats, 2026 revenue guidance midpoint above consensus
LifeMD Inc.
NASDAQ: LFMD
LFMD Trading
22.39% G/L:
$3.6901 Last:
3,978,719 Volume:
$3.50 Open:
LFMD Latest News
LFMD Stock Data
$146,092,411
39,278,882
2.54%
33
N/A
Healthcare Providers & Services
Healthcare
US
New York
